1/67
Looks like no tags are added yet.
A ligand has KD = 20 nM. What fraction of enzyme is bound at 200 nM?
f = [L]/([L]+KD) = 200/220 = 91%
Kinase inhibitor Ki = 10 nM; assay [ATP] = 5 x Km. What IC50 is measured?
IC50 = Ki(1+[S]/Km) = 10 x 6 = 60 nM
Antagonist KB = 10 nM; you want a 5-fold agonist EC50 shift. What [antagonist]?
5 = 1 + [B]/10 nM, so [B] = 40 nM
Agonist EC50 goes 50 nM to 500 nM with 100 nM antagonist. Find KB.
Dose ratio 10; KB = [B]/(ratio-1) = 100/9 = about 11 nM
Antagonist KD = 5 uM, agonist KL = 5 uM, [agonist] = 50 uM. Displacement EC50?
EC50 = KD(1+[L]/KL) = 5 x 11 = 55 uM
Target KD = 1 nM, off-target KD = 10 uM. Selectivity and ideal concentration window?
S = 10^4; about 10 nM to 1 uM
Why are monosaccharides metabolized quickly but sorbitol is not?
Open-chain carbonyl allows glycolysis; reduction to a polyol removes it
Why is monosaccharide-lectin binding weak, and what drives it?
Little net enthalpy (water H-bonds replaced by sugar H-bonds); entropy from displaced water drives binding
How do Tweens and Spans differ?
Tween: high HLB, oil-in-water emulsions. Span: low HLB, water-in-oil emulsions
Why does cellulose resist digestion while starch does not?
Cellulose is beta(1,4): straight chains with dense intra/inter-chain H-bonds. Starch is alpha(1,4): accessible helical chains that amylase cleaves
How does heparin prevent clotting?
S-domain pentasaccharide binds antithrombin (conformational change), which sequesters Factor Xa; no thrombin, no fibrin
What is glycation and which proteins are most affected?
Spontaneous reaction of reducing sugars with Lys (Schiff base, Amadori, AGEs/CML); long-lived proteins such as collagen and hemoglobin
Why are DNA-targeting drugs so toxic, and how is that managed?
Little difference between normal and cancer DNA, so fast-dividing normal cells are hit; dose-limited, combination chemotherapy used
Where does a nitrogen mustard attack DNA, and what are the consequences?
Guanine N7 via aziridinium intermediate; cross-links, depurination, strand scission, G-T mispairing mutations
Minor groove binder vs intercalator?
Minor groove binder: crescent-shaped, shape complementarity, AT-rich. Intercalator: flat fused aromatic stacking between base pairs
Why does the cleavable complex matter for topotecan?
Topotecan stabilizes the covalent Topo I-DNA (Tyr723) intermediate so DNA cannot religate
Why not design enzyme inhibitors from the substrate?
Substrates bind weakly (~90% occupancy is enough; binding energy pays for conformational change). The transition state binds about 10^-16 M, so mimic that
Why is IC50 not a constant?
It depends on [S] (Cheng-Prusoff: IC50 = Ki(1+[S]/Km)); always greater than Ki
Why do very lipophilic drugs permeate poorly?
High k1 (entry) but low k2 (exit): they enter and get trapped in the membrane
How can you tell passive from carrier-mediated transport?
Passive: linear, non-saturable, not inhibited. Carrier: saturable, inhibitable, structure- and cell-specific
Dose-response shapes: competitive antagonist, noncompetitive antagonist, partial agonist, PAM?
Competitive: parallel right shift. Noncompetitive: lower plateau. Partial agonist: lower plateau, agonist-like. PAM: left shift and/or higher plateau
What proves a receptor is constitutively active?
An inverse agonist lowers response below baseline
Why is flumazenil not a NAM?
It does not move the GABA curve; it competes at the benzodiazepine site and reverses PAM effects (null allosteric ligand)
Why can partial agonists help in schizophrenia?
Antagonist-like when dopamine is excessive, agonist-like when low; keeps D2 signaling near target occupancy regardless of metabolism
True or false: raising agonist concentration overcomes a noncompetitive antagonist.
False
True or false: EC50 always equals KD.
False; only when no competing ligand is present
True or false: glycosides are stable in neutral water because they are acetals.
True; hydrolysis needs acid
True or false: peripheral membrane proteins need detergent to extract.
False; integral proteins do. Peripheral ones come off with higher ionic strength
True or false: fructose triggers satiety signaling like glucose does.
False
True or false: voltage-gated channels are opened by first messengers.
False; voltage change opens them, drugs only modulate
Exam 1: Competitive vs noncompetitive antagonist - effect on EC50 and Emax?
Competitive: EC50 up, Emax unchanged (parallel right shift). Noncompetitive: Emax down, EC50 unchanged
Exam 1: Agonist EC50 is 20 nM alone, 220 nM with 50 nM antagonist. Find KB.
Dose ratio 11; KB = 50/10 = 5 nM
Exam 1: Displacement assay antagonist EC50 = 60 nM, [agonist] = 10 nM, KL = 5 nM. Antagonist KD?
KD = 60/(1+2) = 20 nM
Exam 1: Define partial agonist and why it can act as an antagonist.
Intrinsic activity e between 0 and 1; plateau below Emax; displaces a full agonist and lowers response when signaling is high
Exam 1: What does an inverse agonist show about a receptor?
Constitutive activity; it lowers response below baseline by stabilizing the inactive form
Exam 1: Class, mechanism and speed: nicotinic ACh receptor, insulin receptor, estrogen receptor.
LGIC (ms, pore opens); RTK (autophosphorylation, slower); ligand-activated transcription factor (hours)
Exam 1: Flumazenil reverses diazepam but does not shift the GABA curve. What kind of ligand?
Null allosteric ligand; competes at the benzodiazepine site
Exam 1: Why do enzymes bind the transition state tighter than the substrate, and why does it matter?
Binding the TS lowers activation energy; substrates need only ~90% occupancy, so TS mimics (statins) can reach nM or lower
Exam 1: Ki = 4 nM, [S] = 3 Km. IC50? What if [S] doubles?
IC50 = 4(1+3) = 16 nM; at [S] = 6 Km, IC50 = 28 nM (inhibitor looks weaker)
Exam 1: Target KD = 2 nM, off-target KD = 20 uM. Selectivity and ideal range?
S = 10^4; roughly 20 nM to 2 uM
Exam 1: Aspirin and COX-2: inhibition type and residue modified.
Covalent irreversible; acetylates Ser530
Exam 1: Why target the early rate-limiting step of cholesterol synthesis?
Late-step inhibition accumulates toxic intermediates; HMG-CoA reductase controls flux
Exam 2: Why is lipid flip-flop slow but lateral diffusion fast?
Flip-flop requires stripping water from the polar head group through the hydrophobic core; lateral motion needs only weak van der Waals changes
Exam 2: Explain the logD window for passive permeability.
Max about 1 to 2.5. Hydrophilic: low k1. Very lipophilic: high k1 but low k2, trapped
Exam 2: Three differences between passive and carrier-mediated transport.
Linear vs saturable; not inhibitable vs inhibitable; low vs high structure and cell-type specificity
Exam 2: How is a peripheral vs an integral membrane protein removed?
Peripheral: raise ionic strength. Integral: detergent
Exam 2: Why are sorbitol and mannitol IV osmotic diuretics but oral laxatives?
Polar, impermeable, slowly metabolized. IV: raise plasma osmolality, expand plasma volume, more urine. Oral: stay in gut and hold water
Exam 2: What drives sugar-protein binding; how do iminosugars like miglitol gain potency?
Entropy from displaced water; protonated ring N mimics the positively charged TS, binding Asp/Glu
Exam 2: Compare cellulose, starch, glycogen.
Cellulose: beta(1,4), straight, not digestible, structural. Starch: alpha(1,4) with alpha-1,6 branches every 12-30, digestible, plant storage. Glycogen: alpha, branches every 8-12, animal storage
Exam 2: How does heparin inhibit clotting?
S-domain pentasaccharide binds antithrombin, conformational change, Factor Xa sequestered, no thrombin, no fibrin
Exam 2: How does a nitrogen mustard cross-link DNA?
N lone pair displaces Cl-, aziridinium forms, guanine N7 attacks; second arm repeats at another guanine = interstrand cross-link
Exam 2: Consequences of guanine N7 alkylation.
Weak glycosidic bond, depurination, abasic site, strand scission; G-T mispairing, mutations, secondary cancers
Exam 2: Cisplatin's main DNA lesion and effect.
dGpG N7-N7 intrastrand cross-link; bends DNA, stalls RNA polymerase, apoptosis
Exam 2: How does topotecan kill cells?
Traps the Topo I-DNA cleavable complex (Tyr723 phosphoester) so DNA cannot religate
Exam 3: Why are glycosides more stable than free monosaccharides?
They are acetals with no free carbonyl at neutral pH; acid is needed to hydrolyze them
Exam 3: Cyclodextrin structure and pharmaceutical use.
Cyclic alpha(1,4) glucans (6, 7, 8 units); hydrophobic cavity forms inclusion complexes that raise solubility, stability, bioavailability; do not cross membranes
Exam 3: Lactulose - why a laxative and why useful in hepatic encephalopathy?
Not absorbed, osmotic; colon bacteria make acids that trap ammonia
Exam 3: Tamiflu and zanamivir - target, design origin, effect.
Viral neuraminidase; sialic acid mimics; block release of new virions
Exam 3: Why are hemoglobin and collagen most affected by glycation?
Slow reaction (reducing sugar + Lys: Schiff base, Amadori, AGEs) hits long-lived proteins
Exam 3: IC50 for Ki = 10 nM, [S] = 2 Km; EC50 shift for KB = 10 nM antagonist at 30 nM?
IC50 = 30 nM; dose ratio 4 (EC50 up 4-fold)
Exam 3: Competitive vs noncompetitive antagonism, with examples.
Same vs different site; surmountable vs not. Competitive: propranolol, naloxone. Noncompetitive: perampanel
Exam 3: Why does aripiprazole work in both mania and negative symptoms?
D2/D3 partial agonist (e about 0.6); antagonist-like when dopamine is high, agonist-like when low
Exam 3: Suzetrigine mechanism and importance.
NAM of Nav1.8 (voltage-sensing domain, stabilizes closed state); peripheral nociceptor; first non-opioid for moderate-severe acute pain (FDA 2025)
Exam 3: Why are DNA drugs dose-limited and how does combination chemotherapy help?
Poor selectivity; combinations bypass resistance, add distinct mechanisms, and can include repair inhibitors
Exam 3: Compare minor groove binders and intercalators.
Minor groove: crescent-shaped, AT-rich, shape fit, block proteins. Intercalators: flat fused aromatics stacking between base pairs; with enzyme contacts they can poison topoisomerases
Exam 3: A polar drug has good oral bioavailability. What does that suggest, and what risk applies?
Carrier-mediated uptake; efflux pumps may also remove it, so efflux inhibition can raise levels
Exam 3: Define potency, efficacy, affinity; example of high affinity but low efficacy.
Potency = EC50 position; efficacy = Emax; affinity = 1/Kd. Antagonists or partial agonists
Exam 3: Why does more agonist weaken an antagonist in a displacement assay?
EC50 = KD(1+[L]/KL); EC50 rises as [L] rises